Publications by authors named "S V Semochkin"
Article Synopsis
- The trial was a phase 3 study comparing enasidenib, an oral IDH2 inhibitor, to standard care regimens in older patients with late-stage acute myeloid leukemia (AML) who had already undergone multiple treatments.
- The primary goal was to evaluate overall survival (OS), but while the OS results were similar (6.5 months for enasidenib vs. 6.2 months for standard care), enasidenib showed significant improvements in secondary outcomes like event-free survival (EFS), overall response rate (ORR), and transfusion independence (TI).
- Despite not meeting the primary endpoint for OS, the findings suggest that enasidenib could offer important benefits in managing relapsed or refractory AML in
Prognostic value of N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP) was analyzed in patients with multiple myeloma complicated by dialysisdependent renal failure. The prospective study included 20 patients with newly diagnosed multiple myeloma. The concentrations of NT-proBNP were measured before antimyeloma chemotherapy.
View Article and Find Full Text PDFBackground: As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and dexamethasone has shown promising results in phase 1/2 trials of patients with relapsed or refractory multiple myeloma. We aimed to assess the efficacy and safety of this triplet regimen in patients with relapsed or refractory multiple myeloma who previously received lenalidomide.
View Article and Find Full Text PDFBackground: The efficacy and safety of lenalidomide as maintenance therapy after chemotherapy-based second-line therapy in patients with chronic lymphocytic leukaemia is unknown. Although kinase inhibitors can improve outcomes for some patients with relapsed and refractory disease, not all patients have access to these novel drugs. In this study, we aimed to assess the efficacy and safety of lenalidomide as maintenance therapy in patients with previously treated chronic lymphocytic leukaemia.
View Article and Find Full Text PDFAim: To assess the significance of gene expression of the vascular endothelial growth factor-A (VEGF-A) and its interacting receptors VEGFR1 and VEGFR2 as potential diagnostic and prognostic molecular markers in patients with myelodysplastic syndrome (MDS).
Material And Methods: A real time polymerase chain reaction (RT-PCR) assay was used to investigate the gene expression of VEGF-A, VEGFR1, and VEGFR2 in the mononuclear cell fractions obtained from 24 patients with MDS.
Results: The expression of the 3 genes was identified in all the patients examined.